Equities research analysts expect Regeneron Pharmaceuticals Inc (NASDAQ:REGN) to report $5.13 earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Seven analysts have made estimates for Regeneron Pharmaceuticals’ earnings, with estimates ranging from $3.66 to $5.73. Regeneron Pharmaceuticals posted earnings of $5.23 per share in the same quarter last year, which would suggest a negative year over year growth rate of 1.9%. The firm is expected to announce its next earnings report on Thursday, February 14th.
According to Zacks, analysts expect that Regeneron Pharmaceuticals will report full year earnings of $20.65 per share for the current fiscal year, with EPS estimates ranging from $18.21 to $22.49. For the next financial year, analysts anticipate that the firm will report earnings of $22.43 per share, with EPS estimates ranging from $19.08 to $26.12. Zacks’ earnings per share averages are an average based on a survey of sell-side research firms that cover Regeneron Pharmaceuticals.
Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its quarterly earnings data on Tuesday, November 6th. The biopharmaceutical company reported $5.87 earnings per share for the quarter, beating the consensus estimate of $4.94 by $0.93. Regeneron Pharmaceuticals had a net margin of 28.24% and a return on equity of 30.24%. The firm had revenue of $1.66 billion during the quarter, compared to analysts’ expectations of $1.64 billion. During the same quarter last year, the company posted $3.99 EPS. The company’s quarterly revenue was up 10.8% compared to the same quarter last year.
In other Regeneron Pharmaceuticals news, Director Joseph L. Goldstein sold 2,000 shares of the stock in a transaction that occurred on Monday, September 24th. The stock was sold at an average price of $388.65, for a total transaction of $777,300.00. Following the transaction, the director now directly owns 13,000 shares in the company, valued at approximately $5,052,450. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Michael S. Brown sold 1,500 shares of the stock in a transaction that occurred on Wednesday, August 22nd. The stock was sold at an average price of $380.49, for a total value of $570,735.00. Following the transaction, the director now owns 1,500 shares in the company, valued at $570,735. The disclosure for this sale can be found here. Insiders sold 110,052 shares of company stock worth $44,651,762 over the last quarter. 12.42% of the stock is currently owned by company insiders.
Institutional investors have recently bought and sold shares of the business. Icon Wealth Partners LLC purchased a new position in shares of Regeneron Pharmaceuticals in the 2nd quarter valued at about $112,000. Signaturefd LLC increased its stake in shares of Regeneron Pharmaceuticals by 123.8% during the 2nd quarter. Signaturefd LLC now owns 358 shares of the biopharmaceutical company’s stock worth $124,000 after purchasing an additional 198 shares in the last quarter. Flagship Harbor Advisors LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 2nd quarter worth approximately $159,000. Columbia Asset Management purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $196,000. Finally, Ingalls & Snyder LLC purchased a new position in shares of Regeneron Pharmaceuticals during the 3rd quarter worth approximately $204,000. Hedge funds and other institutional investors own 66.06% of the company’s stock.
Shares of Regeneron Pharmaceuticals stock traded down $0.91 on Thursday, hitting $363.34. The stock had a trading volume of 533,631 shares, compared to its average volume of 846,837. Regeneron Pharmaceuticals has a twelve month low of $281.89 and a twelve month high of $416.49. The company has a debt-to-equity ratio of 0.10, a current ratio of 2.49 and a quick ratio of 2.92. The company has a market capitalization of $38.64 billion, a P/E ratio of 27.09, a P/E/G ratio of 1.20 and a beta of 1.34.
About Regeneron Pharmaceuticals
Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.
Featured Story: How much money do you need to begin day trading?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.